Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 3/20 | 0.47 |
| ▸ | FCER2 | P06734 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNG | P07510 | 1/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.45 |
| ▸ | CHRND | Q07001 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | BRS3 | P32247 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14122916 | 0.89 | CAPN1 (0.53) | MMP2MMP9MMP8CTSLCTSB | |
| SCHEMBL8397400 | 0.87 | ANPEP (0.54) | MMP1FCER2MMP8ANPEP | |
| SCHEMBL8348444 | 0.83 | KMT2A (0.54) | KMT2AMMP2MMP8CTSB | |
| SCHEMBL7762733 | 0.83 | KMT2A (0.54) | KMT2AMMP2MMP8CTSB | |
| SCHEMBL7762722 | 0.83 | KMT2A (0.54) | KMT2AMMP2MMP8CTSB | |
| SCHEMBL8343183 | 0.83 | KMT2A (0.54) | KMT2AMMP2MMP8CTSB | |
| SCHEMBL7207282 | 0.83 | KMT2A (0.54) | KMT2AMMP2MMP8CTSB | |
| SCHEMBL7207278 | 0.83 | KMT2A (0.54) | KMT2AMMP2MMP8CTSB | |
| SCHEMBL8344939 | 0.83 | FCER2 (0.56) | MMP1FCER2MMP8ANPEP | |
| SCHEMBL7762727 | 0.83 | FCER2 (0.56) | MMP1FCER2MMP8ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| EP-2968536-B1 | METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY | US HEALTH (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023037254-A1 | METHODS AND COMPOUNDS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | DIDENKO KIRILL (MX) | 2023-03-16 | — | — | WO | disclosed |
| US-20220184111-A1 | METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220105157-A1 | Compositions and Methods for Promoting Angiogenesis in the Eye | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-04-07 | — | — | US | disclosed |
| US-11285169-B2 | Methods for modulating chemotherapeutic cytotoxicity | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | ITGB1 3464/4885ITGA4 4287/4885KMT2A 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.